HUP0203300A2 - Immunoszuppresszáns 2,4-diamino-pirimidin vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents

Immunoszuppresszáns 2,4-diamino-pirimidin vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk

Info

Publication number
HUP0203300A2
HUP0203300A2 HU0203300A HUP0203300A HUP0203300A2 HU P0203300 A2 HUP0203300 A2 HU P0203300A2 HU 0203300 A HU0203300 A HU 0203300A HU P0203300 A HUP0203300 A HU P0203300A HU P0203300 A2 HUP0203300 A2 HU P0203300A2
Authority
HU
Hungary
Prior art keywords
amino
alkyl
immunosuppressants
pharmaceutical compositions
compositions containing
Prior art date
Application number
HU0203300A
Other languages
English (en)
Inventor
Todd Andrew Blumenkopf
Eileen Elliott Mueller
Eric Jan Roskamp
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HUP0203300A2 publication Critical patent/HUP0203300A2/hu
Publication of HUP0203300A3 publication Critical patent/HUP0203300A3/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

A találmány tárgyát azok az (I) általános képletű vegyületek vagy azokgyógyszerészetileg elfogadható sói, szolvátjai vagy hidrátjai képezik,ahol A jelentése minden egyes előfordulásakor egymástól függetlenül CHvagy N; X jelentése a -CH2-, -O-, -NH-, (1-6 szénatomos alkil)-amino-,(1-6 szénatomos alkil)-amino-karbonil-amino-, (1-6 szénatomos alkil)-karbonil-amino-, (1-6 szénatomos alkil)-szulfonil-amino, fenil-szulfonil-amino-, karbonil, -NH-C(O)-, -N-(6-10 szénatomos alkil)-C(O)-, -S(O)y által alkotott csoportból kerül kiválasztásra, ahol yjelentése 0, 1 vagy 2, és n értéke a -(CH2)n csoport esetében 1, 2vagy 3; R1, R2 és R3 jelentését pedig a leírás tartalmazza. Atalálmány tárgyát képezik továbbá az (I) általános képletűvegyületeket tartalmazó gyógyszerkészítmények, valamint az autoimmunbetegségek, a gyulladás, az allergia, a transzplantátum kilökődés, ésegyéb olyan körülmények kezelésére szolgáló eljárások, ahol azimmunoszuppresszív hatóanyag beadása kedvező terápiás eredményt nyújt. Ó
HU0203300A 1999-11-30 2000-11-09 2,4-diaminopyrimidine compounds useful as immunosuppressants, pharmaceutical compositions containing them and their use HUP0203300A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16822499P 1999-11-30 1999-11-30
PCT/IB2000/001628 WO2001040215A1 (en) 1999-11-30 2000-11-09 2,4-diaminopyrimidine compounds usful as immunosuppressants

Publications (2)

Publication Number Publication Date
HUP0203300A2 true HUP0203300A2 (hu) 2003-02-28
HUP0203300A3 HUP0203300A3 (en) 2003-10-28

Family

ID=22610621

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203300A HUP0203300A3 (en) 1999-11-30 2000-11-09 2,4-diaminopyrimidine compounds useful as immunosuppressants, pharmaceutical compositions containing them and their use

Country Status (33)

Country Link
EP (1) EP1242403B1 (hu)
JP (1) JP3955468B2 (hu)
KR (1) KR20020059826A (hu)
CN (1) CN1402720A (hu)
AP (1) AP2002002530A0 (hu)
AT (1) ATE315036T1 (hu)
AU (1) AU1047601A (hu)
BG (1) BG106695A (hu)
BR (1) BR0015995A (hu)
CA (1) CA2392971C (hu)
CO (1) CO5261519A1 (hu)
CZ (1) CZ20021703A3 (hu)
DE (1) DE60025385T2 (hu)
EA (1) EA200200411A1 (hu)
EE (1) EE200200275A (hu)
ES (1) ES2253266T3 (hu)
GT (1) GT200000200A (hu)
HN (1) HN2000000264A (hu)
HU (1) HUP0203300A3 (hu)
IL (1) IL149103A0 (hu)
IS (1) IS6339A (hu)
MA (1) MA26846A1 (hu)
MX (1) MXPA02005350A (hu)
NO (1) NO20022557D0 (hu)
OA (1) OA12097A (hu)
PA (1) PA8506801A1 (hu)
PE (1) PE20010900A1 (hu)
PL (1) PL355946A1 (hu)
SV (1) SV2002000231A (hu)
TN (1) TNSN00232A1 (hu)
TR (1) TR200201431T2 (hu)
UY (1) UY26455A1 (hu)
WO (1) WO2001040215A1 (hu)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060816A1 (en) * 2000-02-17 2001-08-23 Amgen Inc. Kinase inhibitors
EA200300205A1 (ru) * 2000-08-31 2003-06-26 Пфайзер Продактс Инк. Производные пиразола и их применение в качестве ингибиторов протеинкиназы
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2422377C (en) 2000-09-15 2010-04-13 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1345922B1 (en) 2000-12-21 2006-05-31 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
KR20050032105A (ko) 2002-08-02 2005-04-06 버텍스 파마슈티칼스 인코포레이티드 Gsk-3의 억제제로서 유용한 피라졸 조성물
US20040204458A1 (en) 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
DE10237423A1 (de) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
KR20060133552A (ko) * 2004-01-16 2006-12-26 노파르티스 아게 2,4-디아미노피리미딘 및 심장근육발생 유도를 위한 그의용도
ATE512144T1 (de) * 2004-10-12 2011-06-15 Decode Genetics Ehf Peri-substituierte bicyclische arylsulfonamide gegen arterielle verschlusskrankheiten
US20060161001A1 (en) * 2004-12-20 2006-07-20 Amgen Inc. Substituted heterocyclic compounds and methods of use
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
KR20080095902A (ko) 2006-02-14 2008-10-29 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제의 억제제로서 유용한 디하이드로디아제핀
AU2007227602A1 (en) * 2006-03-16 2007-09-27 Novartis Ag Heterocyclic organic compounds for the treatment of in particular melanoma
BRPI0811204A8 (pt) 2007-05-10 2015-09-22 Bristol Myers Squibb Co Tetra-hidroibenzo-1,4-diazepinas substituídas por arila e heteroarila e uso das mesmas para bloquear a recaptação de norepinefrina, dopamina e serotonina
BRPI0818338A2 (pt) * 2007-10-16 2015-04-22 Daiichi Sankyo Co Ltd Composto de pirimidil indolina
RU2012116526A (ru) 2009-09-25 2013-10-27 Вертекс Фармасьютикалз Инкорпорейтед Способы получения производных пиримидина, применимых в качестве ингибиторов протеинкиназы
RU2012116525A (ru) 2009-09-25 2013-10-27 Вертекс Фармасьютикалз Инкорпорейтед Способы получения перемидиновых производных, пригодных в качестве ингибиторов протеинкиназ
TWI513694B (zh) * 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
KR101708761B1 (ko) * 2012-04-13 2017-02-21 주식회사 머쉬메드 퓨린 유도체 또는 그의 염을 포함하는 아토피성 피부염의 예방 또는 치료용 조성물
WO2015054317A1 (en) 2013-10-07 2015-04-16 Kadmon Corporation, Llc Rho kinase inhibitors
WO2019000683A1 (zh) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
US11390609B2 (en) 2017-06-30 2022-07-19 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
ES2930804T3 (es) 2017-06-30 2022-12-22 Beijing Tide Pharmaceutical Co Ltd Inhibidor de proteína cinasa asociada a RHO, composición farmacéutica que lo comprende, así como método de preparación y uso del mismo

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
EP0837063A1 (en) * 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
GB9905075D0 (en) * 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
ATE315036T1 (de) 2006-02-15
TR200201431T2 (tr) 2002-09-23
DE60025385T2 (de) 2006-08-24
PA8506801A1 (es) 2002-04-25
NO20022557L (no) 2002-05-29
AU1047601A (en) 2001-06-12
IL149103A0 (en) 2002-11-10
HUP0203300A3 (en) 2003-10-28
CN1402720A (zh) 2003-03-12
MXPA02005350A (es) 2002-12-11
OA12097A (en) 2006-05-04
BR0015995A (pt) 2002-08-06
DE60025385D1 (de) 2006-03-30
JP2003515602A (ja) 2003-05-07
AP2002002530A0 (en) 2002-06-30
WO2001040215A1 (en) 2001-06-07
KR20020059826A (ko) 2002-07-13
PL355946A1 (en) 2004-05-31
EP1242403A1 (en) 2002-09-25
NO20022557D0 (no) 2002-05-29
EA200200411A1 (ru) 2002-10-31
GT200000200A (es) 2002-05-23
HN2000000264A (es) 2001-05-21
PE20010900A1 (es) 2001-09-08
EE200200275A (et) 2003-10-15
MA26846A1 (fr) 2004-12-20
CA2392971C (en) 2008-10-07
ES2253266T3 (es) 2006-06-01
IS6339A (is) 2002-04-12
SV2002000231A (es) 2002-07-16
BG106695A (bg) 2002-12-29
CA2392971A1 (en) 2001-06-07
CZ20021703A3 (cs) 2003-06-18
UY26455A1 (es) 2001-07-31
JP3955468B2 (ja) 2007-08-08
CO5261519A1 (es) 2003-03-31
EP1242403B1 (en) 2006-01-04
TNSN00232A1 (fr) 2005-11-10

Similar Documents

Publication Publication Date Title
HUP0203300A2 (hu) Immunoszuppresszáns 2,4-diamino-pirimidin vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0300544A2 (hu) Integrin expresszálás inhibitorokat tartalmazó gyógyszerkészítmények
HUP0204580A2 (hu) Arilgyűrűvel kondenzált azapoliciklusos vegyületek és ezeket tartalmazó gyógyszerkészítmények
HUP0301625A2 (hu) Réztartalmú amin-oxidáz inhibitor hatású 1,3,4-oxadiazin-vegyületek, eljárás az előállításukra és alkalmazásuk gyógyszerkészítmények előállítására
AU4437896A (en) Piperidine derivatives having tachykinin antagonist activity
HUP0400710A2 (hu) Tioéter helyettesítővel helyettesített imidazokinolinszármazékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
AU4264396A (en) Cosmetic or pharmaceutical compositions containing mangiferin or derivatives thereof
DE69935153D1 (de) Benzamide als kaliumkanal-inhibitoren
DE60024604D1 (de) Xanthinderivate und analoge als zellsignalisierung inhibitoren
JO2321B1 (en) 4-phenyl-pyridine derivatives
DE60025848D1 (en) Pyrimidin-derivate als selective inhibitoren von cox-2
HUP0101963A2 (hu) Interleukin-1béta átalakító enzim szukcinamid inhibitorai
DE69426836D1 (de) Antivirale 2,4-pyrimidindion-derivate und verfahren zu ihrer herstellung
NO308654B1 (no) Amid-derivater, fremgangsmÕter og mellomprodukter for fremstilling derav, deres anvendelse og farmasøytiske blandinger som inneholdende dem
HUP0002929A2 (hu) Tachikinin receptor antagonista hatású 2-acilamino-propán-aminok és az ezeket tartalmazó gyógyszerkészítmények
DE60019086D1 (de) Zusammensetzungen zur behandlung von hautkrankheiten
DK1150667T3 (da) Langkædet cyclohexenonalkohol til behandling af amytrofisk lateralsklerose
HUP0103166A2 (hu) Karbamát- és karbamidtartalmú készítmények, és neurotróf alkalmazásuk
IL114968A (en) 1,4-dihydropyridine compounds and pharmaceutical compositions containing them
HUP0001773A2 (hu) Szubsztituált tetrahidropiridinszármazékok, eljárás előállításukra, továbbá a vegyületeket tartalmazó gyógyászati készítmények
ES2121218T3 (es) Fenoxifenilciclopentenilhidroxiureas.
TR200100059T2 (tr) Yeni antimikrobik bileşimler
HUP0203270A2 (hu) Hidroxánsav-származék mint a humán CD23 termelés inhibitora, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0202710A2 (hu) Vitronektin receptor antagonisták, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
NZ543068A (en) Substituted 4-(alkyl-amide)-piperidine derivatives, processes for their preparation, and pharmaceutical compositions containing them